Viral vectors in cancer immunotherapy /

Viral Vectors in Cancer Immunotherapy, Volume 379 in the International Review of Cell and Molecular Biology presents the latest on cancer immunotherapy and how it has transformed cancer treatment through advances in immune checkpoint inhibitors and adoptive cell therapy.

Bibliographic Details
Corporate Author:	ScienceDirect (Online service)
Format:	eBook
Language:	English
Published:	[S.l.] : Academic Press, 2023.
Series:	International review of cell and molecular biology ; volume 379
Subjects:	Cancer > Immunotherapy. Cancer > Gene therapy. Genetic vectors > Therapeutic use. Immunotherapy. Cancer vaccines. Gene therapy. Immunotherapy Cancer Vaccines Oncolytic Virotherapy Oncolytic Viruses Genetic Therapy Cancer > Immunothérapie. Cancer > Thérapie génique. Vecteurs de clonage > Emploi en thérapeutique. Immunothérapie. Vaccins anticancéreux. Thérapie génique. Cancer > Gene therapy Cancer > Immunotherapy Electronic books.
Online Access:	Connect to the full text of this electronic book

Table of Contents:

Front Cover
Series page
International Review of CELL AND MOLECULARBIOLOGY
Copyright
Contents
Contributors
Chapter One: Viral vectors engineered for gene therapy
1 Introduction
2 Viral vectors for gene therapy
3 Gene therapy applications using viral vectors
3.1 Cancer therapy
3.2 Cardiovascular and metabolic diseases
3.3 Hematological diseases
3.4 Neurological disorders
3.5 Muscular diseases
3.6 Immunodeficiency
3.7 Infectious diseases
3.8 Other diseases
4 Challenges for viral vector-based gene therapy
5 Conclusions and perspectives
References
Chapter Two: Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicityCheckpoint blockade meets gene therapy
1 Introduction
2 Immune checkpoints in cancer immunotherapy
3 Types of antibodies used in cancer immunotherapy
4 Local delivery of immune checkpoint inhibitors: Prospects for gene therapy
5 Oncolytic viruses expressing ICIs
6 Non-oncolytic vectors expressing ICIs
7 Self-amplifying RNA vectors expressing ICIs
8 Combination of vectors expressing ICIs with other therapies
8.1 Combination with systemically administered ICIs
8.2 Combination with CAR-T cells
8.3 Combination with depletion of immunosuppressive cells
8.4 Combination with radiation and chemotherapy
9 Conclusions
Competing interests
Acknowledgements
References
Chapter Three: Armored modified vaccinia Ankara in cancer immunotherapy
1 Introduction
2 MVA as potent immune activator
2.1 Cell and tissue tropism
2.2 Innate immune activation
2.3 Induction of cell death
2.4 Generation of adaptive immune responses
3 Tumor antigens encoded in MVA vaccines
3.1 HER2
3.2 P53
3.3 Brachyury
3.4 5T4
3.5 MUC1 and CEA
3.6 Self- and virus-derived neoantigens.
3.7 Novel TAA candidates
4 MVA cancer vaccines expressing immune modulatory molecules
4.1 MVA-TRICOM
4.2 MVA-CD40L
4.3 MVA-IL-2
4.4 Novel candidates
5 Maximizing MVA cancer vaccine effectiveness: A comprehensive exploration of delivery routes
5.1 Alternative immunization routes to enhance MVA-based immune modulation
5.2 The impact of immunization routes on the efficacy of armed MVA
6 Conclusions and outlook
References
Chapter Four: Alphaviruses in cancer immunotherapyAlphaviruses in cancer immunotherapy
1 Introduction
2 Alphavirus vectors
2.1 Recombinant particles
2.2 Oncolytic alphaviruses
2.3 RNA replicon vectors
2.4 DNA replicon vectors
3 Alphavirus-based cancer therapy
3.1 Antitumor, cytotoxic, and suicide genes
3.2 Cancer vaccines
3.3 Cancer immunotherapy
3.4 Oncolytic alphaviruses
4 Alphaviruses in comparison to other approaches
4.1 Conventional non-viral vectors versus self-replicating alphavirus DNA vectors
4.2 Other viral vectors versus recombinant self-replicating alphavirus particles
4.3 Synthetic mRNA molecules versus self-replicating RNA replicons
5 Conclusions
References
Chapter Five: Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical successOncolytic viruses as treatment for adult and pediatric high-grade gliomas
1 High-grade gliomas
2 Oncolytic viruses
3 Adult high-grade glioma clinical trials
3.1 Herpes simplex virus type-1(HSV-1)
3.2 Adenoviruses
3.3 Other oncolytic viruses
4 Pediatric high-grade glioma clinical trials
5 Discussion and future perspectives
References
Chapter Six: Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapiesOncolytic viruses in hematological malignancies.
1 Introduction
2 Families of oncolytic viruses and mechanisms of action
2.1 General biology of viruses
2.2 Family of viruses with potential application in oncolytic therapy
2.3 Virotherapy principles: cell signaling and immunopathogenesis in viral infection response
2.4 Viral oncolytic strategies, cell signaling disruption, and immune reprogramming
3 Virotherapy approaches in hematological malignancies
3.1 Precursor myeloid malignancies
3.2 Precursor lymphoid malignancies
3.3 Myeloproliferative neoplasms
3.4 Mature lymphoid malignancies
3.4.1 B cell-derived malignancies
3.4.2 T cell-derived malignancies
3.5 Multiple myeloma
3.6 Combinatorial strategies to enhance immunogenic cell death
4 Conclusion
References
Chapter Seven: Oncolytic virotherapy in lung cancerOncolytic virotherapy in lung cancer
1 The lung cancer scenario
2 Immune therapy in lung cancer
3 Oncolytic virotherapy
3.1 DNA viruses
3.1.1 Adenoviruses
3.1.2 Poxviruses
3.1.3 Herpesvirus
3.1.4 Parvovirus
4 RNA viruses
4.1 Paramyxovirus
4.2 Rhabdovirus
4.3 Orthomyxovirus
4.4 Picornavirus
4.5 Reovirus
5 Discussion
Acknowledgments
References
Chapter Eight: Rational selection of an ideal oncolytic virus to address current limitations in clinical translationRational selection of an ideal oncolytic virus to address current limitations in clinical translation
1 Introduction
2 Oncolytic virus landscape
2.1 Adenovirus
2.2 Herpes simplex virus
2.3 Vaccinia virus
2.4 Reovirus
2.5 Measles virus
3 Ideal properties of an oncolytic virus therapy
4 Vesicular stomatitis virus
4.1 Selectivity
4.2 Therapeutic transgenes
4.3 Genome stability
5 Conclusion
Competing interests
Acknowledgments
References
Backcover.